
Please try another search
By Senad Karaahmetovic
Shares of Seagen (NASDAQ:SGEN) are down over 7% after Bloomberg News reported that talks with Merck (NYSE:MRK) are stalling.
The two companies have not been able to agree on a takeover price, although talks could still resume and ultimately result in a full agreement.
Merck has been looking to acquire Seagen to boost its oncology presence given the exposure to Keytruda, the best-selling cancer treatment. Merck already invested in Seagen two years ago in a $4.5 billion partnership agreement to develop an experimental breast cancer treatment.
Talks between the two sides come after Co-founder and CEO Clay Siegall resigned earlier this year as he is against the sale of the company.
A Needham & Company analyst commented:
“We expect the stock to trade lower on the news today, as the likelihood of a deal materializing, for which some expectation has been baked into the stock over the past 2+ months, now appears to be incrementally lower.”
The WSJ reported in June that Merck is aiming to acquire Seagen for roughly $40 billion. The news sent SGEN shares up about 13%.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.